Target intelligence / Profile preview

Solute carrier family 30 member 8 (SLC30A8)

Target
SLC30A8
Molecular classification
Transporter
01

Overview

Solute carrier family 30 member 8 (SLC30A8), commonly known as zinc transporter 8 (ZnT8), is a proton-coupled zinc antiporter predominantly expressed in the secretory granules of pancreatic beta cells. It plays a critical role in glucose homeostasis by transporting cytosolic zinc into insulin secretory granules, where zinc ions are essential for the crystallization, stabilization, and storage of insulin. Genetic studies have highlighted SLC30A8 as a major locus in diabetes; common variants like the rs13266634 polymorphism increase susceptibility to type 2 diabetes (T2D), whereas rare loss-of-function (LoF) mutations confer significant protection against T2D by enhancing glucose-stimulated insulin secretion. Additionally, ZnT8 is a major autoantigen in type 1 diabetes (T1D), with autoantibodies against it serving as key diagnostic biomarkers. Therapeutic strategies targeting SLC30A8 include the development of small-molecule inhibitors or RNAi therapeutics to mimic the protective LoF phenotype for T2D, as well as monoclonal antibodies (such as mAb43 and Isle43) designed to mask the extracellular epitopes of ZnT8, thereby shielding beta cells from autoimmune destruction in T1D.

Other names
Zinc transporter 8ZnT-8ZnT8Proton-coupled zinc antiporter SLC30A8
02

Mechanism of action

Antigenic masking of cell-surface ZnT8 to prevent autoimmune recognition; Inhibition of zinc transport activity to enhance insulin secretion

03

Biological functions

Zinc transportInsulin storageInsulin maturationInsulin secretionBlood glucose regulationIntracellular zinc ion homeostasis
04

Disease associations

Type 2 diabetesType 1 diabetesDiabetic kidney disease
05

Safety considerations

Potential for altered insulin secretion and glucose homeostasis if ZnT8 function is excessively or inappropriately inhibitedTransient impairment in metabolism during developmentPotential extra-pancreatic effects, such as increased risk of hemolytic anemia or decreased mean corpuscular hemoglobin (MCH)
06

Interacting drugs

Isle43

1 more in the full profile.

07

Biomarkers

ZnT8 autoantibodies (ZnT8A)rs13266634 single nucleotide polymorphism (Arg325Trp)SLC30A8 loss-of-function mutations (e.g., Arg138Ter, Gln174Ter, Lys34SerfsTer50)SLC30A8 promoter hypermethylation

Beyond the preview

Go deeper on Solute carrier family 30 member 8 (SLC30A8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 30 member 8 (SLC30A8).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call